UGT1A9 and neoplasm: Therefore, our study aims to determine whether CYP3A4- and UGT1A9-mediated sorafenib metabolism is differentially affected in HCC patient tumor hepatic microsomes (THLMs) in comparison with those in adjacent normal hepatic microsomes (NHLMs) and commercial hepatic microsomes (CHLMs).